Small molecules in the treatment of COVID-19

S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

[HTML][HTML] A review of the antibacterial, fungicidal and antiviral properties of selenium nanoparticles

DA Serov, VV Khabatova, V Vodeneev, R Li… - Materials, 2023 - mdpi.com
The resistance of microorganisms to antimicrobial drugs is an important problem worldwide.
To solve this problem, active searches for antimicrobial components, approaches and …

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …

CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling… - The Lancet, 2022 - thelancet.com
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …

CKH Wong, ICH Au, KTK Lau, EHY Lau… - The Lancet Infectious …, 2022 - thelancet.com
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

[HTML][HTML] Feline infectious peritonitis: European advisory board on cat diseases guidelines

S Tasker, DD Addie, H Egberink, R Hofmann-Lehmann… - Viruses, 2023 - mdpi.com
Feline coronavirus (FCoV) is a ubiquitous RNA virus of cats, which is transmitted faeco-
orally. In these guidelines, the European Advisory Board on Cat Diseases (ABCD) presents …

Nitazoxanide and COVID-19: a review

HM Al-Kuraishy, AI Al-Gareeb, E Elekhnawy… - Molecular biology …, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is a current global illness triggered by
severe acute respiratory coronavirus 2 (SARS-CoV-2) leading to acute viral pneumonia …

A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients

C Brogna, L Montano, ME Zanolin… - Journal of Medical …, 2024 - Wiley Online Library
The bacteriophage behavior of SARS‐CoV‐2 during the acute and post‐COVID‐19 phases
appears to be an important factor in the development of the disease. The early use of …

Molnupiravir: A versatile prodrug against SARS-CoV-2 variants

D Teli, P Balar, K Patel, A Sharma, V Chavda, L Vora - Metabolites, 2023 - mdpi.com
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

[HTML][HTML] Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

L Song, S Gao, B Ye, M Yang, Y Cheng, D Kang… - … Pharmaceutica Sinica B, 2024 - Elsevier
The main protease (M pro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy
for its high conservation and major role in the virus life cycle. The covalent M pro inhibitor …

[HTML][HTML] SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand …

RS Tumskiy, AV Tumskaia, IN Klochkova… - Computers in Biology …, 2023 - Elsevier
The main (Mpro) and papain-like (PLpro) proteases are highly conserved viral proteins
essential for replication of the COVID-19 virus, SARS-COV-2. Therefore, a logical plan for …